How do you choose the best predicate device for substantial equivalence?

When preparing a 510(k) submission, selecting the most appropriate predicate device is one of the most critical strategic decisions a manufacturer will make. This choice forms the foundation of the substantial equivalence (SE) argument. The process can become particularly complex when a new device, such as an AI-powered diagnostic software or an implant with a novel material, has similarities to several legally marketed devices but is not identical to any single one. Navigating this selection process carefully is essential for building a strong SE argument and achieving a predictable regulatory outcome. The core of the 510(k) program, as outlined in regulations like 21 CFR Part 807, is demonstrating that a new device is at least as safe and effective as a legally marketed device—the predicate. The selection process involves a detailed comparison of the new device's intended use and technological characteristics against potential predicates. For devices with novel features or multiple potential comparison devices, a well-defined strategy, often informed by early engagement with the FDA, is key to success. ### Key Points * **Same Intended Use is Non-Negotiable:** The new device and the predicate device must have the same intended use. Significant differences in intended use or indications for use are a common reason for a Not Substantially Equivalent (NSE) determination. * **Detailed Technological Comparison is Required:** Sponsors must conduct a thorough comparison of design, materials, principles of operation, energy sources, and performance specifications. * **One Primary Predicate:** A 510(k) submission must be based on a single primary predicate device. The entire SE argument must be anchored to this one device. * **"Split Predicates" are Not Permitted:** A sponsor cannot combine the intended use from one predicate with the technological characteristics of another to form the basis of an SE claim. * **Reference Devices Add Support:** While the SE argument is based on a single predicate, data from other legally marketed "reference devices" can be used to support the safety and effectiveness of specific features or technologies that differ from the primary predicate. * **Q-Submission Provides Clarity:** For complex cases involving novel technology, multiple potential predicates, or significant technological differences, using the Q-Submission program to get FDA feedback on the predicate selection strategy is highly recommended. ### Understanding the Core Principles of Predicate Selection #### The Foundational Role of Intended Use The first and most important step in predicate selection is identifying a legally marketed device with the same intended use as the new device. Intended use defines the general purpose of the device and what it is meant to do. The indications for use provide more specific details about the disease or condition the device is intended to diagnose, treat, prevent, cure, or mitigate, as well as the target patient population. Any differences in the indications for use must not alter the intended use or raise different questions of safety and effectiveness. If a new device's intended use is fundamentally different from all available predicates, the 510(k) pathway may not be appropriate, and another pathway like the De Novo process might be necessary. #### Comparing Technological Characteristics Once a potential predicate with the same intended use is identified, the sponsor must conduct a detailed comparison of its technological characteristics against the new device. These characteristics include: * **Design and Materials:** This involves comparing physical specifications, components, and the materials used in patient-contacting parts. * **Principles of Operation:** How the device achieves its intended purpose (e.g., the algorithm in a software device, the mechanical action of an implant). * **Performance Specifications:** Bench testing data demonstrating the device performs as intended. This includes accuracy, reliability, and mechanical strength, among other factors. If there are technological differences between the new device and the predicate, the sponsor must demonstrate that these differences do not raise different questions of safety or effectiveness. This is typically accomplished by providing robust performance data—including non-clinical bench testing, biocompatibility, software validation, and, if necessary, animal or clinical data. ### Scenarios in Predicate Selection #### Scenario 1: A New Device with Multiple Potential Predicates Consider a manufacturer developing a new orthopedic bone screw with a novel surface coating designed to improve integration. They identify two potential predicates: * **Predicate A:** An orthopedic screw with the exact same core design (size, thread pitch, material) but with a standard, uncoated surface. * **Predicate B:** An orthopedic screw with a different design but with a similar, though not identical, surface coating technology. **What FDA Will Scrutinize:** FDA will focus on whether the chosen predicate provides the strongest basis for comparison. Choosing Predicate A makes the argument about the screw's mechanical performance straightforward, but requires extensive data to characterize the new surface coating. Choosing Predicate B simplifies the argument for the coating but requires data to demonstrate that the different core design is equivalent. **Strategic Approach:** In this case, Predicate A is often the stronger choice. The fundamental intended use and mechanical function are identical, isolating the "difference" to the new surface coating. The sponsor can then focus on providing comprehensive performance data (e.g., biocompatibility, mechanical testing) to demonstrate that the new coating does not negatively impact safety or effectiveness. This creates a more direct and defensible SE argument. #### Scenario 2: A Device with a Novel Feature Imagine a company develops a wearable heart monitor. The device's core function of recording and displaying an ECG waveform is identical to numerous legally marketed devices. However, the new device includes a novel AI-based algorithm that provides an alert for a specific, previously undetected arrhythmia. **What FDA Will Scrutinize:** FDA will accept the comparison to a standard ECG monitor for the core technology. However, the agency will require a robust demonstration of the new AI algorithm's performance and clinical validity. The SE argument cannot be fully supported by the predicate alone because the predicate lacks this novel technological feature. **Strategic Approach:** The sponsor would select a standard wearable ECG monitor as the primary predicate to establish equivalence for the core hardware and software functions. For the novel AI algorithm, the sponsor must provide extensive performance data, including validation against a clinical dataset, to demonstrate it is as safe and effective as the predicate's established function. They might also cite "reference devices" (if any exist with similar AI technology in other applications) to support their testing methodology. Given the novelty, this scenario is an ideal candidate for a Q-Submission to discuss the validation plan for the AI feature with FDA. ### Strategic Considerations and the Role of Q-Submission Choosing the "best" predicate is about choosing the device that allows for the most direct and defensible argument for substantial equivalence, minimizing the number and complexity of differences that must be resolved through performance testing. When facing ambiguity—such as with a novel technology, multiple viable predicates, or when unsure about the testing required to address technological differences—engaging with the FDA is the best path forward. The Q-Submission program allows sponsors to request feedback on their proposed predicate and testing strategy *before* investing significant resources in a 510(k) submission. This early feedback can prevent major delays or an NSE determination during review. As of 2024, early communication with the agency remains a best practice for innovative medical devices. ### Key FDA References - FDA Guidance: general 510(k) Program guidance on evaluating substantial equivalence. - FDA Guidance: Q-Submission Program – process for requesting feedback and meetings for medical device submissions. - 21 CFR Part 807, Subpart E – Premarket Notification Procedures (overall framework for 510(k) submissions). ## How tools like Cruxi can help Navigating the predicate selection process requires meticulous organization and documentation. Tools like Cruxi can help regulatory teams systematically research potential predicates, build detailed comparison tables, and manage the extensive documentation and performance data needed to support a substantial equivalence argument. By centralizing this critical information, teams can ensure their 510(k) submission is built on a solid, well-documented foundation. This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program.